BRTX
NASDAQ · Biotechnology
Biorestorative Therapies Inc
$1.56
+0.03 (+1.96%)
Financial Highlights (FY 2026)
Revenue
1.10M
Net Income
-43,744,179
Gross Margin
93.4%
Profit Margin
-3,959.4%
Rev Growth
+44.2%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 93.4% | 93.4% | 51.7% | 51.7% |
| Operating Margin | -4,350.0% | -3,915.0% | 20.5% | 20.6% |
| Profit Margin | -3,959.4% | -3,761.4% | 16.4% | 14.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.10M | 766.2K | 1.76M | 1.61M |
| Gross Profit | 1.03M | 715.4K | 911.0K | 830.3K |
| Operating Income | -48,057,742 | -29,998,590 | 360.9K | 330.2K |
| Net Income | -43,744,179 | -27,305,979 | 288.6K | 237.9K |
| Gross Margin | 93.4% | 93.4% | 51.7% | 51.7% |
| Operating Margin | -4,350.0% | -3,915.0% | 20.5% | 20.6% |
| Profit Margin | -3,959.4% | -3,761.4% | 16.4% | 14.8% |
| Rev Growth | +44.2% | +44.2% | +14.5% | +14.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 3.68M | 4.15M |
| Total Equity | — | — | 7.11M | 6.97M |
| D/E Ratio | — | — | 0.52 | 0.59 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -47,415,078 | -31,241,728 | 503.0K | 417.7K |
| Free Cash Flow | — | — | 335.8K | 390.7K |